Top Markets
#1 Black Phoenix Black Phoenix +828.22%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.74%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +25.29%
#4 Bless Bless +21.01%
#5 SAFEcoin SAFEcoin +20.57%
#6 pipedog pipedog +20.53%
#7 Magma Finance Magma Finance +20.34%
#8 PondCoin PondCoin +20.03%
#9 Beam Beam +19.60%
#10 YFSX YFSX +16.01%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
China Resources Jiangzhong Pharmaceutical Co.,Ltd China Resources Jiangzhong Pharmaceutical Co.,Ltd

China Resources Jiangzhong Pharmaceutical Co.,Ltd

600750
Classement en actions #6126
China Resources Jiangzhong Pharmaceutical Co.,Ltd functions as a prominent... China Resources Jiangzhong Pharmaceutical Co.,Ltd functions as a prominent Chinese manufacturer of a wide array of pharmaceutical products for the domestic market. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, such as tablets designed for stomach-strengthening and digestion promotion, lactobacillus tablets, and triple live bifidobacterium enteric-coated capsules. Other significant OTC offerings feature compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, Fritillaria and loquat capsules, bezoar and snake gallbladder Fritillaria liquid, and compound gold melon seed. Beyond pharmaceutical drugs, the company also provides health consumer goods. These range from general nourishing products and rehabilitation nutrition items to specialized solutions for gastrointestinal and liver health. Furthermore, China Resources Jiangzhong Pharmaceutical manufactures prescription drugs. This segment encompasses a broad selection of Traditional Chinese Medicine (TCM) products, including Shenbao capsules, Paishi granules, Huangba Shengmai drink, Bazhen Yimu capsules, Zhenju Jiangya tablets, Shuangju granules, Zhikang tablets, and Shuxiong granules. It also produces chemical medications such as lumbrokinase enteric-coated capsules, Rabelagat sodium enteric-coated tablets, and chloroprocaine hydrochloride. Additionally, the company processes and supplies essential medicinal raw materials, including stir-fried Chinese jujube seeds, French pinellia, and vinegar-soaked northern bupleurum. The company, headquartered in Nanchang, China, was established in 1996. It was formerly identified as Jiang Zhong Pharmaceutical Co.,Ltd before officially adopting its current name, China Resources Jiangzhong Pharmaceutical Co.,Ltd, in January 2025.
Prix de l'action
$3.48
Capitalisation boursière
$2.21B
Changement (1 jour)
2.21%
Changement (1 an)
12.93%
Pays
CN
Échange China Resources Jiangzhong Pharmaceutical Co.,Ltd (600750)

Catégorie

Healthcare
Revenus pour China Resources Jiangzhong Pharmaceutical Co.,Ltd (600750)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de China Resources Jiangzhong Pharmaceutical Co.,Ltd, le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour China Resources Jiangzhong Pharmaceutical Co.,Ltd de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN